Clinical Cancer Research Targets Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Clinical Cancer Research 13, 7388, December 15, 2007. doi: 10.1158/1078-0432.CCR-07-0411
© 2007 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klatte, T.
Right arrow Articles by Belldegrun, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klatte, T.
Right arrow Articles by Belldegrun, A. S.

Imaging, Diagnosis, Prognosis

Hypoxia-Inducible Factor 1{alpha} in Clear Cell Renal Cell Carcinoma

Tobias Klatte1, David B. Seligson2, Stephen B. Riggs1, John T. Leppert1, Maria K. Berkman1, Mark D. Kleid1, Hong Yu2, Fairooz F. Kabbinavar3, Allan J. Pantuck1 and Arie S. Belldegrun1

Authors' Affiliations: Departments of 1 Urology, 2 Pathology and Laboratory Medicine, and 3 Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California

Requests for reprints: Arie S. Belldegrun, Department of Urology, David Geffen School of Medicine at UCLA, 66-118 CHS Los Angeles, CA 90095-1738. Phone: 310-206-1434; Fax: 310-206-5343; E-mail: abelldegrun{at}mednet.ucla.edu.


   Abstract
Top
 Abstract
Patients and Methods
 Results
 Discussion
 References
 
Purpose: Hypoxia-inducible factor-1{alpha} (HIF-1{alpha}) plays an important role in tumoral adaptation to hypoxic conditions by serving as a transcription factor for several crucial proteins, including vascular endothelial growth factor and carbonic anhydrase IX (CAIX). Here, we evaluated the significance of HIF-1{alpha} in renal cell carcinoma (RCC).

Experimental Design: Immunohistochemical analysis was done on a tissue microarray constructed from paraffin-embedded primary tumor specimens from 357 patients treated by nephrectomy for RCC. Nuclear expression was evaluated by a single pathologist who was blinded to outcome. The expression levels were associated with pathologic variables and survival.

Results: HIF-1{alpha} expression was greater in RCC than in benign tissue. Clear cell RCC showed the highest expression levels. In clear cell RCC, HIF-1{alpha} was significantly correlated with markers of apoptosis (p21, p53), the mammalian target of rapamycin pathway (pAkt, p27), CXCR3, and proteins of the vascular endothelial growth factor family. HIF-1{alpha} was correlated with CAIX and CAXII in localized, but not in metastatic RCC. HIF-1{alpha} expression predicted outcome in metastatic patients: patients with high HIF-1{alpha} expression (>35%) had significantly worse survival than patients with low expression (≤35%); median survival, 13.5 versus 24.4 months, respectively (P = 0.005). Multivariate analysis retained HIF-1{alpha} and CAIX expression as the strongest independent prognostic factors for patients with metastatic clear cell RCC.

Conclusions: HIF-1{alpha} is an important independent prognostic factor for patients with metastatic clear cell RCC. Because HIF-1{alpha} and CAIX are independently and differentially regulated in metastatic clear cell RCC, both tumor markers can be complementary in predicting prognosis.

Renal cell carcinoma (RCC) represents the most lethal urologic malignancy, accounting for >200,000 new cases and >100,000 deaths worldwide annually (1). The incidence of RCC has been steadily increasing at a rate of 2% to 3% per year across the past several decades (2, 3).

Recent achievements in the basic sciences have led to an increased understanding of the molecular pathways underlying the various RCC subtypes. In 1995, Wang et al. (4) isolated hypoxia-inducible factor 1{alpha} (HIF-1{alpha}), which plays a central role in RCC tumorigenesis by acting as a transcription factor for several proteins that are important in tumoral adaptation to a tissue microenvironment that is low in oxygen (5). In a physiologic microenvironment, HIF-1{alpha} is rapidly degraded through the ubiquitin-proteasome pathway (6), but under hypoxic conditions, HIF-1{alpha} is stabilized and accumulates (7) due to the inactivation or absence of the von Hippel-Lindau tumor suppressor gene (VHL; refs. 8, 9) and via activation of other independent mechanisms such as the mammalian target of rapamycin pathway (10). HIF-1{alpha} regulates angiogenesis, tumor growth, progression, metastatic spread, and glucose metabolism by acting as a transcription factor for crucial proteins such as vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), epidermal growth factor receptor (EGFR), insulin-like growth factor (IGF), glucose transporters (GLUT-1), chemokine receptors (CXCR), and carbonic anhydrase IX (CAIX) and XII (CAXII; ref. 5). In addition, HIF-1{alpha} plays an important role in regulating the cell cycle and apoptosis (11, 12). Despite its unquestioned role as a central regulator of tumoral pathophysiology, very little has been attempted in exploring HIF-1{alpha}'s prognostic role in RCC. In a recent Western blot–driven study among 66 patients with clear cell RCC, high HIF-1{alpha} expression was paradoxically found to be a favorable prognostic factor (13). However, in a separate study, the same group evaluated 176 tumor specimens using immunohistochemistry, and found that the survival difference between low and high HIF-1{alpha} expressors did not reach statistical significance (14). The prognostic role of HIF-1{alpha} in clear cell RCC therefore remains unclear. Moreover, a comprehensive correlative expression analysis of HIF-1{alpha} and its upstream and downstream targets has thus far not been done. In this report, we present an immunohistochemical study of HIF-1{alpha}, correlate expression levels to upstream and downstream proteins, and evaluate the prognostic role of HIF-1{alpha} in a large cohort with RCC.


   Patients and Methods
Top
 Abstract
 Patients and Methods
Results
 Discussion
 References
 
Patients. Our study cohort consisted of 357 patients who underwent nephrectomy for sporadic RCC at the University of California, Los Angeles between 1989 and 2000. Following approval by the UCLA Institutional Review Board, a retrospective study was done with outcome assessment based on chart review of clinical and pathologic data. Clinical data included age, gender, and Eastern Cooperative Oncology Group performance status (ECOG PS; ref. 15). Pathologic data included tumor-node-metastasis stage (16), histologic subtype (17), and Fuhrman grade (18). Localized RCC was defined as N0M0 RCC, whereas metastatic RCC was defined if regional lymph node metastasis and/or distant metastasis were present.

Tissue microarray construction. The respective formalin-fixed paraffin-embedded primary tumor specimens were obtained from the Department of Pathology, UCLA Medical Center. Three core tissue biopsies, 0.6 mm in diameter, were taken from selected morphologically representative regions of each paraffin-embedded RCC and precisely arrayed using a custom-built instrument as described previously (19). Additional core tissue biopsies were taken from morphologically benign-appearing surrounding renal parenchyma tissue for each tumor. Sections of the resulting tumor tissue microarray block, 4 µm thick, were transferred to glass slides using the paraffin sectioning aid system (adhesive-coated slides PSA-CS4x, adhesive tape, UV lamp; Instrumedics, Inc.) to support the cohesion of 0.6 mm array elements.

Immunohistochemistry and evaluation of expression. The sections were heated at 56°C for 30 min, deparaffinized with xylene, and rehydrated with a descending series of ethanol. Immunohistochemical staining was done with a Dako Envision staining system (Dako). After endogenous peroxidase blocking with 0.03% H2O2 for 5 min, HIF-1{alpha} antigens were retrieved by pressure cooking in sodium citrate (770 W for 15 min, then 330 W for 15 min). Blocking of nonspecific protein binding was accomplished by incubation with 0.5% 2-nitro-5-thiobenzoate buffer for 30 min. The sections were then incubated or 60 min at room temperature with an anti–HIF-1{alpha} mouse monoclonal antibody (mouse IgG2b, clone H1{alpha}67-sup, final concentration, 6 µg/mL; Novus Biologicals). Subsequently, the sections were incubated with an anti–mouse-conjugated peroxidase-labeled secondary antibody (Dako Envision, Dako) for 30 min on room temperature. Afterwards, the sections were incubated with biotinyl tyramide amplification reagent (Perkin-Elmer) at room temperature for 10 min. The sections were visualized with the application of diaminobenzidine substrate chromagen solution and hematoxylin counterstain.

The expression was evaluated by one anatomic pathologist (D.B. Seligson) in a blinded fashion to validate the diagnostic morphology of each array spot. The evaluation of expression involved site and degree of reactivity. Site of reactivity included evaluation of the relevant histologic subtype, as well as the subcellular localization (i.e., nucleus, cytoplasm). Degree of reactivity included evaluation for maximal staining intensity using a 0 to 3 scale (0, negative; 1, weak; 2, moderate; 3, strong), as well as the percentage of positive cells at each stated intensity. The overall score used for subsequent statistical analysis was the pooled mean from the three spots of the same tumor. The HIF-1{alpha} assay required tyramide amplification in order to appreciate the protein signals, and negative control IgG2b-stained sections showed occasional, predominantly cytoplasmic staining (diffuse or coarsely granular), particularly in normal renal tubules as well as in stromal cells. These were considered background stainings. Sections stained with anti–HIF-1{alpha} also showed similar cytoplasmic background staining. Hence, only clearly specific nuclear localization of the HIF-1{alpha}–stained sections was included in the scoring.

Statistical analysis. The Kruskal-Wallis test was used for comparing expressions among pathologic variables. Correlation was assessed with the Pearson coefficient. The end point of this study was disease-specific survival time. Death from RCC was considered the event, whereas death from other reasons was censored at the date of death. The Kaplan-Meier method was used to generate the survival functions. To allow univariate survival analysis (log-rank test), we dichotomized the patient cohort according to a cutoff which was identified using recursive partitioning–based survival tree analysis. Univariate survival analysis was also done using univariate Cox regression analysis. Independent prognostic variables of survival were identified with a multivariate Cox regression analysis. To avoid overfitting of the regression model by using a dichotomized, categorical expression, we used a continuous marker expression. A significance level of 0.05 was used for all statistical tests. The statistical packages SPSS and R4 were used for the analyses.


   Results
Top
 Abstract
 Patients and Methods
 Results
Discussion
 References
 
HIF-1{alpha} overexpression in clear cell RCC. Normal renal tubules of both morphologically normal tissue and tumor tissue showed only rare scattered nuclear staining of HIF-1{alpha}. No staining of HIF-1{alpha} was observed in the glomeruli. Scattered positive nuclei, however, were seen in lymphoid clusters and rarely in endothelial cells. Tumors tended to have either predominantly negative or predominantly positive cells throughout each patient sample (Fig. 1 ).


Figure 1
View larger version (85K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Expression of HIF-1{alpha} by immunohistochemistry in renal tissues (top, magnification, x10; bottom, magnification, x40). A, morphologically normal cortical renal tissue demonstrating a lack of nuclear HIF-1{alpha} staining. Cytoplasmic background staining from the tyramide amplification system was seen in distal and proximal tubules and was disregarded in the scoring. B, low-grade clear cell RCC with well-defined scattered HIF-1{alpha} nuclear staining. C, high-grade clear cell RCC demonstrating abundant and heavy staining with frequent and strongly positive nuclear expression in tumor cells.

 
HIF-1{alpha} staining intensities were generally increased in RCC compared with normal tissue (mean intensity, 0.4); clear cell had the highest mean intensity (1.3), followed by chromophobe (0.8), collecting duct (0.7), and papillary RCC (0.6). In addition to intensity, the greatest staining frequencies were also observed in the clear cell subtype (Fig. 2 ).


Figure 2
View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. HIF-1{alpha} expression frequency according to histologic subtype. Clear cell (mean expression ± SE, 30 ± 1; n = 308), papillary (12 ± 3, n = 37), chromophobe (15 ± 5, n = 8), and collecting duct RCC (15 ± 8, n = 4) had higher expression than normal renal tissue (3 ± 1).

 
Because the highest HIF-1{alpha} expression was observed in clear cell RCC, subsequent analyses were only done for 308 patients with the clear cell variant of RCC. The characteristics of these patients are summarized in Table 1 . No meaningful differences in HIF-1{alpha} expression were noted when the samples from clear cell patients were stratified according to T stage (P = 0.08), N stage (P = 0.46), M stage (P = 0.61), and Fuhrman grade (P = 0.93), but levels inversely correlated with tumor size (R = –0.14, P = 0.01).


View this table:
[in this window]
[in a new window]

  		Table 1. Patient and tumor characteristics

 
HIF-1{alpha} expression correlates with upstream and downstream proteins. We have previously reported on the expression levels of p21, p27, p53, CAIX, CAXII, CXCR3, phosphorylated Akt (pAkt), PTEN, VEGF-A, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2, and VEGFR-3 evaluated on the tumors of the same patients. Analysis of the relationship between HIF-1{alpha} expression and a panel of relevant kidney cancer tumor markers revealed a significant correlation with CAIX, CAXII, p21, p53, proteins of the mammalian target of rapamycin pathway (p27, pAkt), and proteins of the VEGF family (Table 2 ). HIF-1{alpha} was found to correlate with CAIX and CAXII only in localized (R = 0.23, P = 0.003 and R = 0.24, P = 0.003, respectively), but not in metastatic disease (R = 0.04, P = 0.63 and R = 0.12, P = 0.18, respectively). Conversely, a majority of the other tumor markers tested were significantly correlated in both localized and metastatic disease.


View this table:
[in this window]
[in a new window]

  		Table 2. Correlation analyses of HIF-1{alpha} with upstream and downstream proteins

 
Survival. One hundred and forty-five (47%) of the subjects tested died from RCC after a median duration of 1.4 years (range, 0.1-11.6 years). Seventy-six patients died from other causes. The median follow-up of the patients alive was 6.8 years (range, 0.6-16.9 years).

Univariate Cox regression analysis showed no association between HIF-1{alpha} expression and survival in localized disease (P = 0.79), but predicted survival in metastatic RCC with a hazard ratio of 1.008. A 10% increase in HIF-1{alpha} expression was associated with an 8% increased risk of death from RCC (P = 0.04). Recursive partitioning-based survival tree analysis identified an ideal cutoff of 35% for further substratification of the metastatic patients. The 52 patients with high HIF-1{alpha} expression (>35%) had significantly worse survival than the 89 patients with low expression (≤35%); median survival, 13.5 ± 2.6 versus 24.4 ± 5.1 months (P = 0.005; Fig. 3 ). The 1-, 2-, and 5-year survival rates were 51 ± 7%, 34 ± 7%, and 16 ± 5% for patients with high expression, and 69 ± 5%, 50 ± 5%, and 27 ± 5% for patients with low expression. There was no association between HIF-1{alpha} expression and response to immunotherapy (P = 0.19).


Figure 3
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Kaplan-Meier survival estimates for patients with metastatic clear cell RCC, substratified in high (>35%) and low (≤35%) HIF-1{alpha} expression.

 
A multivariate Cox regression analysis was done to identify independent prognostic factors for the patients with metastatic clear cell RCC. The variables tested included ECOG PS, T stage, concomitant lymph node metastases, Fuhrman grade, number of metastatic sites and HIF-1{alpha} expression. To avoid overfitting of the model, HIF-1{alpha} expression was entered as a continuous variable. Only ECOG PS (hazard ratio, 1.45; 95% confidence interval, 1.06-2.00; P = 0.02) and HIF-1{alpha} expression (hazard ratio, 1.008; 95% confidence interval, 1.001-1.016; P = 0.03) were independent prognostic factors. Because it has been previously shown that CAIX plays a paramount role in predicting prognosis and response to immunotherapy in metastatic clear cell RCC (20, 21), we included continuous CAIX expression in a second Cox regression analysis. In this analysis, ECOG PS, HIF-1{alpha}, and CAIX expression were all found to be independent prognostic factors for patients with metastatic clear cell RCC. Both CAIX and HIF-1{alpha} were retained the strongest predictors of survival (Table 3 ). Paradoxically, high CAIX but low HIF-1{alpha} correlated with improved survival.


View this table:
[in this window]
[in a new window]

  		Table 3. Multivariate Cox regression analysis

 

   Discussion
Top
 Abstract
 Patients and Methods
 Results
 Discussion
References
 
The main findings of this study are that in metastatic clear cell RCC, (a) nuclear HIF-1{alpha} expression in the primary tumor is an independent prognostic factor, (b) levels of HIF-1{alpha} and CAIX expression are not correlated with each other, implying that each is independently regulated in metastatic disease, and (c) both markers used together improve prognostic modeling.

HIF-1{alpha} expression is affected by oxygen concentration, VHL status, and the activity of interrelated molecular pathways such as the mammalian target of rapamycin pathway (7, 8, 10). Because HIF-1{alpha} is genetically linked to VHL inactivation (8), which occurs in >50% of sporadic clear cell RCCs, we limited our analysis to patients with this subtype. Dysfunction of the VHL protein (through mutation or hypermethylation of the VHL gene) and/or hypoxia lead to reduced degradation of HIF-1{alpha} through the 26S proteasome and thereby lead to intracellular stabilization and accumulation of HIF-1{alpha} (22, 23). HIF-1{alpha} then induces the transcription of several factors including VEGF, PDGF, CXCR, IGF-1, and CAIX (5).

The prognostic role of HIF-1{alpha} in RCC was recently evaluated by Lidgren et al. (13) who investigated HIF-1{alpha} expression of 66 clear cell, 20 papillary, and 6 chromophobe RCCs using Western blot analysis. Mirroring the present immunohistochemistry results, they showed that clear cell RCC had the highest expression of HIF-1{alpha} and that tumoral expression was significantly higher than in nonmalignant renal cortex tissue. No significant associations were observed between HIF-1{alpha} expression and tumor-node-metastasis stage, grade, tumor size, vein invasion, or DNA ploidy. Survival analysis, interestingly, showed that high HIF-1{alpha} expression was a favorable prognostic factor, even in multivariate analysis. Expanding on their findings, Lidgren et al. (14) conducted a immunohistochemical tissue microarray–based study on 176 patients with clear cell RCC. Unlike the Western blot–driven study, the survival difference between high and low expressors in this study did not reach statistical significance, although patients with higher expression tended to have a more favorable prognosis. In contrast with the studies of Lidgren et al., the authors of the present study observed high HIF-1{alpha} expression as an adverse prognostic factor, a finding which is in accordance with the results for other tumor entities (24, 25). This contradictory finding may be explained by the methodology of HIF-1{alpha} analysis used by Lidgren et al. (14), in which cytoplasmic HIF-1{alpha} staining, but not nuclear staining, was analyzed. This implies that the subcellular compartment (nucleus or cytoplasm) is important for the effectiveness of HIF-1{alpha} as it has been shown for other proteins such as p21 (26), and indeed, HIF-1{alpha} is a transcription factor that is active when translocated to the nucleus. Higher HIF-1{alpha} expression in the cytoplasm might indicate that HIF-1{alpha} has been translocated to the cytoplasm, does not transcribe DNA and, therefore, leads to less aggressive tumors and better prognosis. Because high HIF-1{alpha} expression was associated with poor survival, targeting HIF-1{alpha} may be a promising therapeutic approach (27). In fact, antisense HIF-1{alpha} has been shown to inhibit progression and metastasis, and to enhance the chemosensitivity of pancreatic cancer in vivo (28). Because HIF-1{alpha} was not correlated with CAIX, combined administration of antisense HIF-1{alpha} and the CAIX antibody G250 could produce a synergistic effect.

We did a comprehensive correlative analysis of nuclear HIF-1{alpha} expression in the primary tumor with its assumed upstream and downstream targets. We showed significant correlations between HIF-1{alpha} and proteins of the VEGF family, which corroborates the concept that HIF-1{alpha} accumulation leads to enhanced transcription of the respective DNA segments (5, 29–31). VEGF-A is the strongest proangiogenic factor and exerts its role via interaction with VEGFR-1 and VEGFR-2, whereas VEGF-C and VEGF-D are mainly involved in the formation of lymph vessels by interacting with VEGFR-2 and VEGFR-3 (31–33). It seems, however, that not all VEGF proteins are similarly regulated through HIF-1{alpha} accumulation. For example, the expression levels of VEGF-C and VEGFR-2 within the tumor epithelium and HIF-1{alpha} were inversely correlated, implying that VEGF-C is negatively regulated through HIF-1{alpha} in RCC, consistent with the concept that VEGF-C is involved to a greater extent with lymphangiogenesis as opposed to angiogenesis. Correlation analysis also revealed that HIF-1{alpha} regulates chemokine receptors. Most research efforts have been focused on CXCR4, which is involved in cancer progression through its proangiogenic and immunomodulating properties (34, 35). Our data indicates that CXCR3, which has angiogenesis-inhibitory and immune enhancing effects (36), may also be regulated through HIF-1{alpha}. Additionally, it has been recently shown that HIF-1{alpha} is involved in apoptosis and cell cycle regulation by controlling p53 (12). It is accepted that hypoxia induces apoptosis by increasing the stability of p53 (37, 38), which itself induces apoptosis by acting as a transcription factor for cell cycle regulators such as p21 or mdm2 (11). It is worth noting that HIF-1{alpha} can only interact with wild-type p53 but not with the tumor-derived mutated p53 (39), reflecting different circumstances in apoptosis regulation through HIF-1{alpha} in benign and malignant tissue. Taken together, our correlation results corroborate the concept that HIF-1{alpha} regulates the cell cycle and apoptosis by modulating p21 and p53. Finally, correlation analysis between HIF-1{alpha} and pAkt and p27 further supports the theory that HIF-1{alpha} crosstalks with proteins of the mammalian target of rapamycin pathway (10, 40, 41).

Carbonic anhydrases are transmembrane enzymes that play a crucial role in the regulation of the pH value by catalyzing the reversible reaction of carbonic acid to carbon dioxide and water (42). Both hypoxia and VHL inactivation lead to increased cellular levels of HIF-1{alpha}, and subsequently, to an increase of carbonic anhydrases, especially of CAIX (43, 44). It has been shown that CAIX is an indicator for survival and response to systemic therapy among patients with metastatic clear cell RCC, with higher levels being associated with improved survival (20) and enhanced response to interleukin 2–based immunotherapy (21). Our investigation indicates that HIF-1{alpha}, CAIX, and CAXII are differentially regulated in localized and metastatic clear cell RCC. Expressions of these proteins were only significantly correlated in localized RCC. We hypothesize that carbonic anhydrases and HIF-1{alpha} may be regulated independently in metastatic RCC. In fact, Ihnatko et al. (45) recently described that CAIX expression in human glioblastoma cells was increased via a hypoxia-independent mechanism. Similar or other mechanisms can be assumed in RCC (42). It is therefore possible that CAIX expression in metastatic RCC reflects VHL status, whereas HIF-1{alpha} expression might be more complex and be regulated by additional mechanisms and molecular pathways.

In conclusion, our data on HIF-1{alpha} expression in a large number of primary RCC cases shows that nuclear HIF-1{alpha} is an important indicator of prognosis in patients with metastatic clear cell RCC, with high HIF-1{alpha} expression predicting poor survival. Because they are not associated with each other, HIF-1{alpha} and CAIX may represent ideal complementary markers for predicting prognosis and may allow improved patient selection for systemic therapies. Integration of these markers in established prognostic models will result in more accurate survival prediction and will guide patient selection for systemic therapies. Finally, it is evident that CAIX and HIF-1{alpha} are differentially regulated in metastatic RCC.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: T. Klatte and D.B. Seligson contributed equally to this work.

4 http://cran.r-project.org Back

Received 2/16/07; revised 7/23/07; accepted 9/14/07.


   References
Top
 Abstract
 Patients and Methods
 Results
 Discussion
 References
 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108.[Abstract/Free Full Text]
  2. Chow WH, Devesa SS, Warren JL, Fraumeni JF. Rising incidence of renal cell cancer in the United States. JAMA 1999;281:1628–31.[Abstract/Free Full Text]
  3. Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of Surveillance, Epidemiology and End Results program data. J Urol 2002;167:57–60.[CrossRef][Medline]
  4. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995;270:1230–7.[Abstract/Free Full Text]
  5. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 2003;9:4641–52.[Abstract/Free Full Text]
  6. Salceda S, Caro J. Hypoxia-inducible factor 1{alpha} (HIF-1{alpha}) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997;272:22642–7.[Abstract/Free Full Text]
  7. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A 1993;90:4304–8.[Abstract/Free Full Text]
  8. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Up-regulation of hypoxia-inducible factors HIF-1{alpha} and HIF-2{alpha} under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 2000;19:5435–43.[CrossRef][Medline]
  9. Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Jr., Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996;93:10595–9.[Abstract/Free Full Text]
  10. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1{alpha} expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60:1541–5.[Abstract/Free Full Text]
  11. Schmid T, Zhou J, Brune B. HIF-1 and p53: communication of transcription factors under hypoxia. J Cell Mol Med 2004;8:423–31.[Medline]
  12. Greijer AE, van der WE. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 2004;57:1009–14.[Abstract/Free Full Text]
  13. Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Vasko J, Ljungberg B. The expression of hypoxia-inducible factor 1{alpha} is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res 2005;11:1129–35.[Abstract/Free Full Text]
  14. Lidgren A, Hedberg Y, Grankvist K, Rasmuson T, Bergh A, Ljungberg B. Hypoxia-inducible factor 1{alpha} expression in renal cell carcinoma analyzed by tissue microarray. Eur Urol 2006;50:1272–7.[CrossRef][Medline]
  15. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–55.[Medline]
  16. American Joint Committee on Cancer. Kidney. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002. p. 323–5.
  17. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997;183:131–3.[CrossRef][Medline]
  18. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655–63.[Medline]
  19. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844–7.[CrossRef][Medline]
  20. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003;9:802–11.[Abstract/Free Full Text]
  21. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11:3714–21.[Abstract/Free Full Text]
  22. Ivan M, Kondo K, Yang H, et al. HIF{alpha} targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464–8.[Abstract/Free Full Text]
  23. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-{alpha} to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468–72.[Abstract/Free Full Text]
  24. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1{alpha} is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000;60:4693–6.[Abstract/Free Full Text]
  25. Schindl M, Schoppmann SF, Samonigg H, et al. Overexpression of hypoxia-inducible factor 1{alpha} is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002;8:1831–7.[Abstract/Free Full Text]
  26. Weiss RH, Borowsky AD, Seligson D, et al. p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol 2007;177:63–8.[CrossRef][Medline]
  27. Redell MS, Tweardy DJ. Targeting transcription factors for cancer therapy. Curr Pharm Des 2005;11:2873–87.[CrossRef][Medline]
  28. Chang Q, Qin R, Huang T, Gao J, Feng Y. Effect of antisense hypoxia-inducible factor 1{alpha} on progression, metastasis, and chemosensitivity of pancreatic cancer. Pancreas 2006;32:297–305.[CrossRef][Medline]
  29. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604–13.[Abstract]
  30. Mazure NM, Chen EY, Yeh P, Laderoute KR, Giaccia AJ. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 1996;56:3436–40.[Abstract/Free Full Text]
  31. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795–803.[CrossRef][Medline]
  32. Karkkainen MJ, Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000;19:5598–605.[CrossRef][Medline]
  33. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002;2:573–83.[CrossRef][Medline]
  34. Schioppa T, Uranchimeg B, Saccani A, et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003;198:1391–402.[Abstract/Free Full Text]
  35. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003;425:307–11.[CrossRef][Medline]
  36. Pan J, Burdick MD, Belperio JA, et al. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol 2006;176:1456–64.[Abstract/Free Full Text]
  37. Chen D, Li M, Luo J, Gu W. Direct interactions between HIF-1{alpha} and Mdm2 modulate p53 function. J Biol Chem 2003;278:13595–8.[Abstract/Free Full Text]
  38. Hansson LO, Friedler A, Freund S, Rudiger S, Fersht AR. Two sequence motifs from HIF-1{alpha} bind to the DNA-binding site of p53. Proc Natl Acad Sci U S A 2002;99:10305–9.[Abstract/Free Full Text]
  39. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM. Stabilization of wild-type p53 by hypoxia-inducible factor 1{alpha}. Nature 1998;392:405–8.[CrossRef][Medline]
  40. Box AH, Demetrick DJ. Cell cycle kinase inhibitor expression and hypoxia-induced cell cycle arrest in human cancer cell lines. Carcinogenesis 2004;25:2325–35.[Abstract/Free Full Text]
  41. Pantuck AJ, Thomas G, Belldegrun AS, Figlin RA. Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications. Semin Oncol 2006;33:607–13.[CrossRef][Medline]
  42. Dorai T, Sawczuk I, Pastorek J, Wiernik PH, Dutcher JP. Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: proposal of a unified hypothesis. Cancer Invest 2006;24:754–79.[CrossRef][Medline]
  43. Ivanov SV, Kuzmin I, Wei MH, et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci U S A 1998;95:12596–601.[Abstract/Free Full Text]
  44. Grabmaier K, De Weijert MCA, Verhaegh GW, Schalken JA, Oosterwijk E. Strict regulation of CAIX(G250/MN) by HIF-1{alpha} in clear cell renal cell carcinoma. Oncogene 2004;23:5624–31.[CrossRef][Medline]
  45. Ihnatko R, Kubes M, Takacova M, et al. Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia. Int J Oncol 2006;29:1025–33.[Medline]



This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. Klatte, D. B. Seligson, J. LaRochelle, B. Shuch, J. W. Said, S. B. Riggs, N. Zomorodian, F. F. Kabbinavar, A. J. Pantuck, and A. S. Belldegrun
Molecular Signatures of Localized Clear Cell Renal Cell Carcinoma to Predict Disease-Free Survival after Nephrectomy
Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 894 - 900.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. M. Greenberger, I. D. Horak, D. Filpula, P. Sapra, M. Westergaard, H. F. Frydenlund, C. Albaek, H. Schroder, and H. Orum
A RNA antagonist of hypoxia-inducible factor-1{alpha}, EZN-2968, inhibits tumor cell growth
Mol. Cancer Ther., November 1, 2008; 7(11): 3598 - 3608.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klatte, T.
Right arrow Articles by Belldegrun, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klatte, T.
Right arrow Articles by Belldegrun, A. S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online